This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment.
The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).
Diagnosis of NVG
Patients who have received IVT-AFL treatment according to Japanese labeling.
Patients who are contraindicated based on approved label
Diagnosis of other indication
Participants with a diagnosis of NVG will be enrolled after the decision for treatment with Aflibercept (AFL) has been made by the investigator. Participants who have been prescribed AFL for a medically appropriate use will be eligible to be enrolled. Indications and contraindications according to the local market authorization should be carefully considered.
Cohort
Prospective
Aflibercept (Eylea, BAY86-5321)
DrugAdministration by intravitreal injection
The number of participants with adverse events (AEs)
Intraocular Pressure (IOP) value after study drug administration
In case of transient and/or persistent IOP elevation
Mean changes in Visual Acuity
Proportion of participants with improvement of anterior neovascularization
Map coordinates are unavailable for these locations. Locations are shown below instead.
Japan